Prospects for Engineering HIV-specific Antibodies for Enhanced Effector Function and Half-Life

Current Opinion in HIV and AIDS - United States
doi 10.1097/coh.0000000000000149
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Comprehensive Engineering of Escherichia Coli for Enhanced Expression of IgG Antibodies

Metabolic Engineering
Applied MicrobiologyBiotechnologyBioengineering
2011English

Envelope-Specific Antibodies and Antibody-Derived Molecules for Treating and Curing HIV Infection

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2016English

Engineering Particles for Therapeutic Delivery: Prospects and Challenges

Proceedings of the Royal Society of Victoria
EcologyGeology
2013English

A Transcription Activator-Like Effector Toolbox for Genome Engineering

Nature Protocols
BiochemistryGeneticsMolecular Biology
2012English

Engineering HIV-Specific Immunity With Chimeric Antigen Receptors

AIDS Patient Care and STDs
EnvironmentalPublic HealthInfectious DiseasesOccupational Health
2016English

Engineering Mindset for Life Sciences and Biotechnology

Engineering in Life Sciences
BioengineeringEnvironmental EngineeringBiotechnology
2019English

Transcription Activator–like Effector (TALE) Domain Nucleases for Genome Engineering

Science-Business eXchange
2011English

Prospects for Antisense Peptide Nucleic Acid (PNA) Therapies for HIV

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2009English

S14.2: Protective Antibodies Twice Removed – Prospects for Inherited Passive Immunity

American Journal of Reproductive Immunology
GynecologyReproductive MedicineImmunologyObstetricsAllergy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy